<code id='85CF577738'></code><style id='85CF577738'></style>
    • <acronym id='85CF577738'></acronym>
      <center id='85CF577738'><center id='85CF577738'><tfoot id='85CF577738'></tfoot></center><abbr id='85CF577738'><dir id='85CF577738'><tfoot id='85CF577738'></tfoot><noframes id='85CF577738'>

    • <optgroup id='85CF577738'><strike id='85CF577738'><sup id='85CF577738'></sup></strike><code id='85CF577738'></code></optgroup>
        1. <b id='85CF577738'><label id='85CF577738'><select id='85CF577738'><dt id='85CF577738'><span id='85CF577738'></span></dt></select></label></b><u id='85CF577738'></u>
          <i id='85CF577738'><strike id='85CF577738'><tt id='85CF577738'><pre id='85CF577738'></pre></tt></strike></i>

          Home / comprehensive / leisure time

          leisure time


          leisure time

          author:leisure time    Page View:5771
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In